https://www.selleckchem.com/pr....oducts/msu-42011.htm
3±1.3%), epeleuton 2 g/day significantly decreased HbA1c (-0.4%; P=0.026). Among patients with baseline HbA1c 6.5%, epeleuton 2 g/day decreased HbA1c by 1.1% (P=0.047; n=26). Consistent dose-dependent reductions were observed for fasting plasma glucose, insulin, and insulin resistance indices. Epeleuton 2 g/day decreased circulating markers of cardiovascular risk and endothelial dysfunction. Epeleuton was well tolerated, with a safety profile not different from placebo. Conclusions While epeleuton did not meet its primary end poin
Like
Comment
Share
